{"name":"COMBINATION","title":"","children":[{"id":"ADC","name":"ADC","presenterLast":"ADC","children":[{"id":"1193","name":"1193","title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, abrogates the resistance to T-DM1 in HER2-positive gastric cancer: a preclinical study","presenterFirst":"Yoshikane","presenterLast":"Nonagase","presenterInstitution":"Kindai University Faculty Of Medicine","keywords":"Breast cancer;Drug resistance;Drug resistance;ADC","target":"HER2","tumor":"Gastric","combo":null,"sage":"payload","pharma":"academia"},{"id":"685","name":"685","title":"GPC2 is an oncogene and immunotherapeutic target in high-risk neuroblastoma","presenterFirst":"Kristopher","presenterLast":"Bosse","presenterInstitution":"Children's Hospital of Philadelphia","keywords":"Neuroblastoma;Glypican-2;Glypican-2;N-myc","target":"GPC2","tumor":"Neuroblastoma","combo":null,"sage":"target-tumor","pharma":"academia"},{"id":"4012","name":"4012","title":"Visualisation of EPR effect and active targeting by using microscopic mass spectrometry","presenterFirst":"Masahiro","presenterLast":"Yasunaga","presenterInstitution":"National Cancer Ctr. EPOC","keywords":"Molecular imaging;Antibody;Antibody;Imaging","target":"NA","tumor":"Pancreas","combo":null,"sage":"technology","pharma":"academia"},{"id":"2656","name":"2656","title":"Polatuzumab Vedotin significantly enhances in-vitro cell death and overall survival against CD79b+ Burkitt lymphoma (BL) /Primary Mediastinal Large B cell Lymphoma (PMBL) NSG xenograft mice","presenterFirst":"Aradhana","presenterLast":"Tiwari","presenterInstitution":"New York Medical College","keywords":"B cells;Anticancer therapy;Anticancer therapy;Antibody Engineering","target":"CD79b","tumor":"Lymphoma","combo":null,"sage":"target-tumor","pharma":"academia"},{"id":"47","name":"47","title":"SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression","presenterFirst":"Gulden","presenterLast":"Menderes","presenterInstitution":"Yale Univ. School of Medicine","keywords":"HER-2/neu;Sarcoma/soft-tissue malignancies;Sarcoma/soft-tissue malignancies;Ovarian cancer","target":"HER2","tumor":"Carcinosarcoma","combo":null,"sage":"target-tumor","pharma":"academia"},{"id":"44","name":"44","title":"U3-1402, a novel HER3-targeting ADC, and a novel DNA topoisomerase I inhibitor inhibit the growth of non-small cell lung cancer with EGFR mutation","presenterFirst":"Kimio","presenterLast":"Yonesaka","presenterInstitution":"Kindai University Faculty of Medicine","keywords":"EGFR;Antibody Engineering;Antibody Engineering;Non-small cell lung cancer","target":"HER3","tumor":"Lung","combo":null,"sage":"target-tumor","pharma":"academia"},{"id":"5141","name":"5141","title":"Optimizing peptide-drug conjugate delivery as an alternative to antibody-drug conjugates for solid tumors","presenterFirst":"Theo","presenterLast":"Sottero","presenterInstitution":"Fred Hutchinson Cancer Research Center","keywords":"Antibody;Drug design;Drug design;Pharmacokinetics","target":"NA","tumor":"Many","combo":null,"sage":"other","pharma":"academia"},{"id":"41","name":"41","title":"An Antibody Drug Conjugate targeting HER-3 demonstrates promising antitumor efficacy in a wide range of human cancer","presenterFirst":"Gianluca","presenterLast":"Sala","presenterInstitution":"University of Chieti","keywords":"Targeted therapy;HER-3;HER-3;Immunotherapy","target":"HER3","tumor":"Many","combo":null,"sage":"target-tumor","pharma":"academia"},{"id":"4576","name":"4576","title":"Targeted human cytolytic fusion proteins: an update","presenterFirst":"Stefan","presenterLast":"Barth","presenterInstitution":"University of Cape Town","keywords":"Immunotherapy;Monocyte-derived leukemia;Monocyte-derived leukemia;Triple-negative breast cancer","target":"NA","tumor":"NA","combo":null,"sage":"technology","pharma":"academia"},{"id":"2651","name":"2651","title":"A novel CD19 targeting antibody-drug conjugate, huB4-DGN462, shows promising in vitro and in vivo activity in CD19-positive lymphoma models","presenterFirst":"Francesco","presenterLast":"Bertoni","presenterInstitution":"Institute of Oncology Research - IOR","keywords":"Lymphoma: non-Hodgkin's lymphoma;CD19;CD19;DNA-alkylating","target":"CD19","tumor":"Lymphoma","combo":null,"sage":"target-tumor","pharma":"academia"},{"id":"4591","name":"4591","title":"Specific elimination of invasive and multidrug-resistant cancer cells by an antibody-drug conjugate targeting AXL","presenterFirst":"Julia","presenterLast":"Boshuizen","presenterInstitution":"Netherlands Cancer Institute","keywords":"Melanoma/skin cancers;Intra-tumor heterogeneity;Intra-tumor heterogeneity;Antibody-drug conjugate","target":"AXL","tumor":"Melanoma","combo":null,"sage":"target-tumor","pharma":"academia"},{"id":"3669","name":"3669","title":"Screening platform for development of antibody-drug conjugates against novel targets at the National Research Council of Canada","presenterFirst":"Maria Luz","presenterLast":"Jaramillo","presenterInstitution":"National Research Council","keywords":"Antibody;Targeted drug delivery;Targeted drug delivery;Cancer","target":"NA","tumor":"NA","combo":null,"sage":"target-tumor","pharma":"academia"},{"id":"57","name":"57","title":"Generation and characterization of novel anti-glycan monoclonal antibody against Acute Myeloid Leukemia","presenterFirst":"Chong Kok","presenterLast":"Teo","presenterInstitution":"Bioprocessing Technology Institute","keywords":"Antibody;SLAMF7;SLAMF7;Anti-glycan","target":"SLAMF7","tumor":"Leukemia","combo":null,"sage":"target-tumor","pharma":"academia"},{"id":"4602","name":"4602","title":"The dissociation constant rate of ADC would be an important factor for antitumor activity <i>in vivo</i>","presenterFirst":"Ryo","presenterLast":"Tsumura","presenterInstitution":"National Cancer Center East","keywords":"Monoclonal antibodies;Anticancer therapy;Anticancer therapy;NA","target":"TF","tumor":"Pancreas","combo":null,"sage":"other","pharma":"academia"},{"id":"1701","name":"1701","title":"The novel anti-CD205 Antibody Drug Conjugate (ADC) MEN1309 shows strong antitumoral activity in diffuse large B cell lymphoma (DLBCL)","presenterFirst":"Eugenio","presenterLast":"Gaudio","presenterInstitution":"Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland","keywords":"Antibody;Lymphoma;Lymphoma;Xenografts","target":"CD205","tumor":"Lymphoma","combo":null,"sage":"target-tumor","pharma":"academia"},{"id":"4593","name":"4593","title":"Glycoengineered antibodies for click chemistry applications","presenterFirst":"Drishti","presenterLast":"Sehgal","presenterInstitution":"University of Minnesota","keywords":"Antibody;NA;NA;NA","target":"NA","tumor":"NA","combo":null,"sage":"other","pharma":"academia"},{"id":"4613","name":"4613","title":"Cytotoxicity of selenium trastuzumab and bevacizumab immunoconjugates against triple negative breast cancer cells","presenterFirst":"Soni","presenterLast":"Khandelwal","presenterInstitution":"Texas Tech University","keywords":"Breast cancer;Immunotherapy;Immunotherapy;NA","target":"NA","tumor":"Breast","combo":null,"sage":"payload","pharma":"academia"},{"id":"5242","name":"5242","title":"Further evidence that the DNA-interactive Pyrrolobenzodiazepine (PBD) Dimer SJG-136 works through a transcription factor inhibition mechanism","presenterFirst":"Julia","presenterLast":"Mantaj","presenterInstitution":"King's College London","keywords":"DNA binding;Small molecule drugs;Small molecule drugs;Drug design","target":"NA","tumor":"NA","combo":null,"sage":"payload","pharma":"academia"},{"id":"4615","name":"4615","title":"Development of an antibody-drug conjugate with broad anticancer activity.","presenterFirst":"Siang-Yo","presenterLast":"Lin","presenterInstitution":"Rutgers Cancer Instutute of NJ","keywords":"Antibody;Antigen;Antigen;Targeted drug delivery","target":"NA","tumor":"NA","combo":null,"sage":"target-tumor","pharma":"academia"},{"id":"4589","name":"4589","title":"Preclinical investigation of SGN-CD70A antibody-drug conjugate in T cell lymphomas","presenterFirst":"Chen-Yen","presenterLast":"Yang","presenterInstitution":"UCSF","keywords":"Lymphoma: non-Hodgkin's lymphoma;Antibody;Antibody;T cell lymphoma","target":"CD70A","tumor":"Lymphoma","combo":null,"sage":"target-tumor","pharma":"academia"},{"id":"1141","name":"1141","title":"Evaluation of GABRP as a novel therapeutic target in triple negative breast cancer","presenterFirst":"Vikram","presenterLast":"Wali","presenterInstitution":"Yale Univ. School of Medicine","keywords":"Triple negative breast cancer;Novel anticancer agents;Novel anticancer agents;Targeted therapy","target":"GABRP","tumor":"Breast","combo":null,"sage":"target-tumor","pharma":"academia"},{"id":"CT155","name":"CT155","title":"Phase 2 study of sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate (ADC), in patients with pretreated metastatic small-cell lung cancer (mSCLC)","presenterFirst":"Jhanelle","presenterLast":"Gray","presenterInstitution":"H. Lee Moffitt Cancer Center & Research Institute","keywords":"Trop-2;antibody-drug conjugate;antibody-drug conjugate;NA","target":"Trop-2","tumor":"Lung","combo":null,"sage":"target-tumor","pharma":"academia"}]},{"id":"ADC_other","name":"ADC_other","presenterLast":"ADC_other","children":[{"id":"1820","name":"1820","title":"Synergistic lethality of mAbs with an EMT reversal agent, Nintedanib, in epithelial ovarian cancer","presenterFirst":"Jocelyn","presenterLast":"Teo","presenterInstitution":"A*STAR","keywords":"Monoclonal antibodies;Angiogenesis inhibitor;Angiogenesis inhibitor;NA","target":"NA","tumor":"Ovarian","combo":null,"sage":"target-tumor","pharma":"academia"}]}]}
